Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer

NCT01249352 is registered in ClinicalTrials.gov with Eurofarma Laboratorios S.A. as lead sponsor.

NCT NCT01249352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01249352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
Lead sponsor
Eurofarma Laboratorios S.A.
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2009
Completion date
November 30, 2013
Enrollment
104 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, esophageal cancer